Related Experiment Videos
[The effect of suramin on human lung cancer cell line in vitro]
S Fujiuchi1, T Tsuji, Y Ohsaki
1First Dept. of Internal Medicine, Asahikawa Medical College.
Abstract:
Recently, several investigators reported the effects of suramin, a drug used in the treatment of trypanosomiasis, onchocerciasis, and an inhibition of the binding of some growth factors to cell surface receptors. In present study, therefore, we examined the effects of epidermal growth factor(EGF) and suramin on cell proliferation and cell cycle kinetics of an established cell line from human lung cancer(PC-13). EGF showed a stimulatory effect on cell proliferation of PC-13, suggesting EGF behaves as a growth factor of PC-13. On the other hand, suramin inhibited the stimulatory effect of EGF to PC-13 in a dose dependent manner. In addition, it was also observed that suramin inhibits the cell cycle progression from G0/G1 phase to S phase. These results indicate that suramin may withhold the cell proliferation and cell growth via suppression of the EGF cell stimulatory effects.
Insights
Suramin, an antiparasitic drug, was found to inhibit human lung cancer cell proliferation by blocking epidermal growth factor (EGF) signaling. This drug effectively halts cancer cell cycle progression, suggesting a potential therapeutic role.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Context:
- Epidermal Growth Factor (EGF) is implicated in various cancers, including lung cancer.
- Suramin is an established drug for treating parasitic infections like trypanosomiasis and onchocerciasis.
- Previous research suggests suramin can inhibit growth factor binding to cell receptors.
Purpose:
- To investigate the effects of epidermal growth factor (EGF) and suramin on the proliferation and cell cycle kinetics of a human lung cancer cell line (PC-13).
Summary:
- Epidermal growth factor (EGF) demonstrated a stimulatory effect on PC-13 cell proliferation.
- Suramin inhibited the EGF-induced proliferation of PC-13 cells in a dose-dependent manner.
- Suramin was observed to inhibit cell cycle progression from the G0/G1 to the S phase.
Impact:
- These findings suggest suramin may impede cancer cell proliferation and growth by suppressing EGF-mediated stimulatory effects.
- Suramin's mechanism involves blocking EGF signaling pathways crucial for cancer cell growth.
- This study highlights suramin as a potential agent for targeting EGF-dependent lung cancer growth.